Biomedicine Daily · Saturday, 14 November 2026
CBA FRONTIER INSIGHTS
FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy
The FDA approved Gazyva (obinutuzumab) to induce proteinuria remission in adults with primary membranous nephropathy at risk of disease progression, the first drug approved specifically for this indication. In the pivotal Phase 3 MAJESTY trial (NCT04629248) of 142 patients, 36% of the Gazyva group achieved complete remission at week 104 versus 6% of the tacrolimus group.
Clinical readouts and safety
EGFR-TKI plus chemotherapy yields 34-month PFS in TP53-cocomutated advanced NSCLC
In first-line treatment of advanced NSCLC with EGFR and TP53 co-mutations, a third-generation EGFR-TKI plus chemotherapy achieved a median PFS of 34 months versus 15.6 months with monotherapy, cutting disease progression risk by 56% (HR=0.44, 95% CI 0.32-0.60, P<0.001). The randomized phase III data offer a benchmark for this poor-prognosis subgroup.
OptiTROP-Lung05 poster at CCHIO: sacituzumab tirumotecan plus pembrolizumab cuts progression or death risk 65%
The phase 3 OptiTROP-Lung05 trial, testing sacituzumab tirumotecan plus pembrolizumab as first-line therapy for PD-L1-positive, driver-gene-negative advanced NSCLC, was selected for a poster at the 2026 CCHIO. In the combination arm, the risk of disease progression or death was reduced by 65% (HR=0.35, p<0.0001) versus immunotherapy alone.
ECHELON-1 10-Year Follow-Up Shows 90.3% OS for A+AVD Versus 84.9% for ABVD in Advanced cHL
A post-hoc analysis of 10-year ECHELON-1 follow-up (median 120 months, 1334 patients with newly diagnosed stage III-IV classical Hodgkin lymphoma) shows frontline brentuximab vedotin plus AVD (A+AVD) achieved a 10-year overall survival rate of 90.3% versus 84.9% with ABVD (HR=0.59, 95% CI 0.42-0.83), a 41% reduction in death risk. Peripheral neuropathy was mostly grade 1-2 and improved over time. The OS analysis is post-hoc and descriptive, and no China-specific data were included.
Iza-bren PANKU-Esophagus01 Phase III hits PFS and OS endpoints in JAMA
Baili-Tianheng's iza-bren (BL-B01D1, luncomilintan... ) results from the PANKU-Esophagus01 trial were published in JAMA. In the Phase III randomized study in second-line esophageal squamous cell carcinoma, the bispecific ADC met both primary endpoints, progression-free survival and overall survival, in a head-to-head comparison against standard chemotherapy. This is the drug's third publication in a top international journal within one month.
Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
Regeneron's NPR1-blocking antibody baloncibart (REGN7544) met the primary endpoint in the Phase 2 Pinnacle trial of 82 patients with POTS. A single 450 mg injection reduced the lying-to-standing heart rate increase by 11.4 beats per minute more than placebo at day 8. Regeneron plans to launch a Phase 3 trial.
Beam's Base-Edited Therapy Risto-Cel Keeps All 31 Patients VOC-Free for 12 Months
Beam Therapeutics' base-edited therapy risto-cel, per independent adjudication, achieved at least 12 consecutive months free of severe vaso-occlusive crises (VOCs) in all 31 patients, with all secondary efficacy endpoints met, including 12 consecutive months free of hospitalization for severe VOCs. Beam plans to submit a BLA to the FDA as early as the end of 2026, which, if filed on schedule, would be the first BLA for a base-edited therapy.
Cheap drug may prevent second stroke by lowering blood pressure
A randomized study across five U.S. hospitals found that adding the diuretic spironolactone to usual post-stroke care lowered 3-month systolic blood pressure to 126 mmHg versus 133 mmHg with standard care. Among 160 patients with an average age of 63, 52% on spironolactone reached the below 130/80 target versus 30% on usual care. At 6 months systolic pressure remained about 7 points lower, with similar rates of serious adverse events requiring hospitalization (15% versus 16%); results were reported at the AHA meeting in Chicago.
Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty.
The EPCAT III randomized controlled trial showed that aspirin alone after total hip or total knee arthroplasty was not inferior to 5 days of rivaroxaban followed by aspirin for preventing symptomatic venous thromboembolism. Among 5429 patients, venous thromboembolism occurred in 13/2718 (0.48%) in the aspirin-alone group and 12/2647 (0.45%) in the rivaroxaban-aspirin group, a risk difference of 0.02 percentage points (95% CI -0.34 to 0.39; P<0.001 for noninferiority).
Targeting F. nucleatum with metronidazole plus tislelizumab and fruquintinib in MSS colorectal cancer: A multicenter phase 2 study
A multicenter phase 2 study (Jiang et al., Renji Hospital, NCT06356597) evaluated metronidazole plus tislelizumab and fruquintinib in F. nucleatum-positive MSS metastatic colorectal cancer, showing encouraging clinical activity with manageable toxicity. Mechanistically, metronidazole reduced F. nucleatum load without widespread dysbiosis, and the combination enhanced CD8+ T cell responses. The study advances antimicrobial intervention from animal models to prospective biomarker-selected clinical validation, though the single-arm design lacks randomized data.
New addiction society guidance on medetomidine’s brutal withdrawal
The American Society of Addiction Medicine this week released its first national considerations for recognizing and managing medetomidine withdrawal, which remain considerations rather than formal guidelines pending larger validating studies (verification pending). Medetomidine appears almost always combined with illicit opioids, and naloxone remains first-line for suspected overdose. Withdrawal begins with nausea and vomiting without diarrhea, clonidine is recommended, and intravenous dexmedetomidine in an ICU may be needed if it fails or patients cannot take oral medication; the drug had been detected in at least 18 states by the end of 2025.
RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
A phase 2/3 trial (NCT07935369) will test the Claudin 18.2-targeting ADC RC118 combined with RC148 as first-line treatment for Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. It plans to enroll 680 participants against tislelizumab plus CAPOX. The phase 2 portion explores dose combinations in three arms; the phase 3 portion evaluates progression-free survival at the recommended dose. Not yet recruiting, with a planned start in November 2026.
Regulatory and policy
FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
On November 13, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) plus enfortumab vedotin-ejfv for adults with muscle invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy. The regimen consists of neoadjuvant combination therapy before surgery, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy.
LEO Pharma's Delgocitinib Cream Approved by NMPA for Moderate to Severe Chronic Hand Eczema
LEO Pharma announced that Delgao (delgocitinib cream) has been approved by China's National Medical Products Administration for topical treatment of adults with moderate to severe chronic hand eczema who respond inadequately to topical corticosteroids or for whom they are unsuitable. The approval is based on the DELTA China Phase 3 trial (NCT06004050, 362 participants), a randomized double-blind study that met its primary endpoint, showing statistically significant improvement in CHE severity versus cream vehicle after 16 weeks of treatment. This marks the topical pan-JAK inhibitor's landing in the Chinese market, though efficacy figures at individual visits, pricing, and reimbursement access have not been disclosed.
AbbVie's upadacitinib approved in China for non-segmental vitiligo in patients 12 and older
AbbVie's once-daily 15 mg upadacitinib extended-release tablets received approval from China's NMPA on November 13 for a new indication: non-segmental vitiligo in adults and adolescents aged 12 and older who are candidates for systemic therapy. According to the press release, it is the first and only approved systemic treatment for non-segmental vitiligo in China, and the tenth indication upadacitinib has received in the country. Upadacitinib is a selective, reversible JAK inhibitor developed by AbbVie and is being studied in multiple immune-mediated inflammatory diseases.
STAT+: Enforcement of stringent Medicaid work requirements delayed for six months
The Trump administration announced Friday that it is giving states an additional six months to begin enforcing Medicaid work requirements. Under last year's One Big Beautiful Bill, states that expanded Medicaid must ensure working-age recipients without dependent children work, attend school, or volunteer at least 80 hours per month, unless they are disabled, caring for young children, or medically frail. A federal judge recently rejected the federal government's medical frailty definition and ruled that states lacked sufficient time and resources to overhaul their eligibility systems.
STAT+: Senators introduce bill to curb conflicts of interest on preventive care panel
US Senators Angus King and Elizabeth Warren have introduced a bill setting standards for membership and conflict-of-interest recusal on the US Preventive Services Task Force. It follows STAT reporting that panel members hold stock in pharmaceutical and medical device companies and that two own private practices that could benefit from panel recommendations. Federal officials granted all members waivers allowing them to remain, and the panel has not met in more than a year.
Industry and deals
Windward prices $175M IPO to advance China-licensed lung drugs
Windward Bio completed a $175 million IPO, selling about 10.3 million shares at $17 each, with Sanofi purchasing an additional $50 million in shares through a private placement. Its lead pipeline drug WIN378 is an ultra-long-acting injectable targeting TSLP, and the company says dosing could be as infrequent as twice a year, compared with monthly dosing for Tezspire. The Phase 3 part of its asthma trial began in September, with results expected next year (to be verified).
Cellectis could cut 70% of workforce in shift to in vivo therapies
Two months after Cellectis announced it was abandoning allogeneic CAR-T to move into in vivo gene editing, the company disclosed the restructuring could cut up to 70% of its global workforce. With 229 full-time employees as of Dec. 31, 2025, up to about 160 people could be affected, with the realignment proceeding over the rest of this year and into 2027 (to be verified). The lasme-cel and eti-cel clinical programs have stopped enrollment, and site closeout activities are underway.
PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
PharmaLogic has agreed to buy Lantheus' radiopharmaceutical CDMO and its Springfield, New Jersey production plant for an undisclosed sum, advancing its goal of building the first fully integrated global radiopharmaceutical CDMO. Springfield employees will join Norway's Agilera Pharma, in which PharmaLogic took a majority stake last year, and Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
Arrowhead has submitted Redemplo to the FDA for severe hypertriglyceridemia. Ionis' Tryngolza posted sales of only $9 million and full-year guidance was cut to $50 million (to be verified). Kyverna shelved KYV-102 (to be verified) while miv-cel's stiff person syndrome BLA was accepted by the FDA. Prime Medicine dosed the first patient with PM577a in a Wilson disease Phase 1/2 trial, with initial data expected in 2027.
STAT+: Doctors have questions about the Watchman. Boston Scientific has a sales pitch.
Despite setbacks, Boston Scientific continues to push Watchman sales while physicians hold questions about the implant. More than 800,000 devices have been implanted globally (to be verified). The company acquired it over a decade ago and won approval for a limited patient group after years of FDA dispute, while preparing larger plans.
Research papers
Shanghai Jiao Tong Team Shows TLR4-TIR Has Single-Turnover NADase Activity, ADPR Acts as Molecular Glue
On November 13, a team led by Hu Zehan at Shanghai Jiao Tong University published in Science that the TIR domain of TLR4 is not an enzymatically inert scaffold but has single-turnover NADase activity. The ADPR produced by cleaving NAD+ is not released but retained at the TLR4-TIR/TIRAP-TIR interface, acting as molecular glue that stabilizes the TLR4-TIRAP-MyD88 signaling complex.
NRF2 is a mechanosensitive checkpoint for NLRP3 inflammasome activation.
A Nature paper reports that extracellular matrix stiffness determines NLRP3 inflammasome activity: substrates near physiological stiffness enable human and mouse phagocytes to show in vivo-like NLRP3 activation with lipopolysaccharide as the only signal. Mechanistically, physiological stiffness induces the transcription factor NRF2, which is required for one-signal NLRP3 activation, and its downstream target gene Panx1 promotes NLRP3 activity. The findings link matrix mechanobiology to inflammasome regulation, though the abstract's 'may be' wording leaves NRF2's checkpoint role needing further validation.
Chinese Team Lands Cell Cover with Spatial CRISPR Screen SPAC-seq, Identifying Icam1 and Cd44
A Chinese team developed the spatial CRISPR screening method SPAC-seq with its companion tool TARDIS, linking gene perturbations to spatial phenotypes and signaling pathways; the work appeared on the cover of Cell. The study found that Icam1 loss in tumor cells promotes metastasis through immunosuppression and macrophage polarization, and that Cd44 in CD8+ T cells regulates spatial phenotypes through interaction with Spp1 on macrophages. The team also presented a model in which transcription factor-chemokine receptor axes couple cell state to chemotaxis.
Experimental blood test detects early breast cancer and predicts recurrence
A nucleosome epigenetic blood test developed by teams led by Guy Ron at the Hebrew University of Jerusalem and Efrat Shema at the Weizmann Institute of Science detected early breast cancer with 95% accuracy in blood samples from 77 breast cancer patients and 30 healthy women, at a stage when tumors were still confined to the breast and no larger than 2 centimeters.
Science Reports AI-Monitored Bioadhesive iMAS Cuts Microvascular Anastomosis Surgery Time 78% in Rats
A research team developed iMAS, a bioinspired microneedle adhesive system modeled on tree roots anchoring into soil, integrating sutureless fixation with AI-based real-time monitoring and early warning in a single platform. In a rat model, iMAS shortened microvascular anastomosis surgery time by 78% and inhibited neointimal hyperplasia, supporting active post-transplant monitoring. The study was published in Science as "AI-monitored bioadhesive for sutureless microvascular anastomosis," but sample size, controls, follow-up duration, and whether large-animal or human trials are planned remain undisclosed.
Single-cell analysis of chromatin state and transcriptome in the human basal ganglia.
Researchers built a single-cell multi-omic atlas of histone modifications and transcriptomes across eight basal ganglia regions from neurotypical human donors. Combinatorial expression of homeobox transcription factors distinguishes neuronal identities, and integration with paired MERFISH spatial transcriptomics revealed regional heterogeneity in epigenomic and transcriptional programs. The atlas was used to interpret neuropsychiatric disease-associated noncoding risk variants and to build deep-learning models predicting gene regulatory activity and variant effects.
The genetic landscape of canine tumors: Insights from the Canine Cancer Genome Atlas (CCGA).
The Canine Cancer Genome Atlas (CCGA) aggregates whole-exome data from 667 tumor-normal pairs across 10 canine tumor histotypes, with unified alignment, variant calling, and annotation pipelines. Selection analyses identified 39 cancer drivers, including recurrent TP53, PIK3CA, PTEN, SETD2, MAP3K14, and FAT4 alterations, plus copy number events such as MYC amplifications and PTEN deletions. Direct comparison with matched human cancers reveals conserved and species-enriched oncogenic mechanisms, pathways, and therapeutic contexts; data are downloadable with interactive analyses.
A lysosomal DRAM1-GLUT1-NADPH axis coordinates glucose sensing with metabolic reprogramming.
Li, Long, Ryan and colleagues at the CRUK Scotland Institute report in Molecular Cell a lysosomal glucose-sensing axis: pathophysiological high glucose induces DRAM1 via the MLX/ChREBP complex, and DRAM1 binds newly synthesized GLUT1, trafficking it to lysosomes without degradation. This reduces surface GLUT1, reversibly limiting glucose entry independently of mTORC1 and AMPK, with NADPH as the key downstream metabolic signal and metabolism rewired toward glutamine anaplerosis, creating vulnerability to glutaminase (GLS) inhibition. However, this therapeutic vulnerability rests mainly on in vitro inference, the metabolite profile of Dram1-/- tumors is a correlative in vivo observation, and the axis's generality across tissues and disease contexts remains untested.
Common variation of cell abundances and gene expression in the human striatum.
Using single-nucleus RNA sequencing of 3.9 million nuclei from 178 adult brain donors, researchers characterized inter-individual variation in cell abundance and gene expression in the striatum and prefrontal cortex. Donors with higher astrocyte, microglia, or OPC proportions in one gray-matter region showed the same tendency in all sampled gray-matter regions. OPC proportions in cortex and striatum declined 40% between ages 30 and 80, and donor age predicted from RNA-expression patterns had a median absolute error of 6.6 years.
Once considered junk, cellular 'chimeras' emerge as key to better cancer care
A University of Virginia team has published a study in Science Advances building an atlas of over 569,000 chimeric RNAs across 1,019 cancer cell lines, with an analytical pipeline to predict their functions. Removing chimeric RNA from healthy cells disrupted the cell cycle and reduced cell survival, and the RNA was often malfunctioning in primary breast cancer tumors. The paper's DOI is 10.1126/sciadv.aei0901.
Scientists identify protein driving age-related organ damage
A Monash University team publishing in Immunity reported a mouse study showing that granzyme K drives aging-related damage in the heart, liver and kidneys. Older mice lacking granzyme K had improved heart function and reduced fibrosis, along with fewer signs of aging damage in the liver and kidneys, while their immune systems still aged normally.
Cell changes around early breast cancers provide clues to why some cases become invasive
An MD Anderson team has published in Science a cell atlas of the ductal carcinoma in situ (DCIS) microenvironment, using single-cell and spatial analysis to map more than 850,000 cells from samples of normal breast tissue, DCIS, and invasive breast cancer. The findings may help explain why some DCIS lesions progress to invasive disease. (DOI: 10.1126/science.aef4622)
Gut and urogenital microbiomes influence menopausal hormone therapy outcomes
A 6-month study shows that menopausal hormone therapy induces multi-site microbiome remodeling, including a shift of the vaginal microbiome toward a reproductive-age-like state. Baseline gut and vaginal microbiome types influence clinical response to therapy. Integrating clinical features with gut microbiome features predicts rapid symptom relief, described as a blueprint for precision menopause management.
Mechanical forces enable human stem cell modeling of protein aggregation cardiomyopathy.
Researchers built a human model of CRYAB-R120G desmin-related cardiomyopathy using iPSCs expressing the mutant at near-endogenous levels, finding that three-dimensional mechanical loading, not fatty acid-based metabolic maturation media, is required for Desmin expression (to be verified). In microengineered heart tissues, contractile deficits accompanied impaired calcium handling, suggesting electromechanical uncoupling; the JAK1 inhibitor itacitinib partially rescued contractility (DOI 10.1126/sciadv.aee9464, to be verified).
DeepRNAi: Predicting on- and off-target siRNA activity and establishing a benchmark
DeepRNAi is a deep learning model that predicts on-target and off-target siRNA knockdown activity from siRNA and mRNA sequences. It was trained on 16 million siRNA-transcript pairs from 2,031 siRNAs and incorporates transcript context from biological foundation models (to be verified).
Methods and resources
The deep learning framework Hist2Prot infers single-cell spatial proteomics from histology to predict biomarkers and clinical outcomes
Fan et al. propose Hist2Prot, an AI model that infers single-cell spatial proteomic patterns from routine hematoxylin and eosin (H&E) slides. The model was applied across multiple cohorts to predict molecular biomarkers, prognosis, and immunotherapy response. The study was published in Nature Cancer, DOI 10.1038/s43018-026-01270-8.
Organ-on-chip shows how tumors interact with nerves and blood vessels
Researchers at Linköping University in Sweden and Politecnico di Milano in Italy have built an organ-on-chip model of head and neck cancer that cultures cancer cells, vessel-like structures, and nerves on a stamp-sized chip. An adjustable ECM based on hyaluronic acid, collagen, and laminins altered cancer cell behavior and their response to cisplatin. Tumors in contact with nerves showed less vascular invasion but increased in volume. The paper was published in PNAS, DOI: 10.1073/pnas.2602541123.
The "ever-vaccinated" stock-flow bias in adult RSV vaccine policy evaluation: A methodological caution and a flow-based remedy
A methodological study in Human Vaccines & Immunotherapeutics (Deng and Chen) uses weekly 2025-26 US National Immunization Survey data to decompose adult RSV vaccine cumulative coverage into prior-season stock and current-season flow. A mid-season snapshot as of 2026-02-21 shows coverage of 43.2% among adults 75+ (stock share 84.9%) and 32.8% among high-risk adults 50-74 (stock share 82.9%), with only 15-17% reflecting current-season vaccination. The authors recommend using current-season flow as the primary outcome and stock share as a diagnostic; limitations include the empirical approximation of stock share, underpowered illustrative regional quasi-experiments, and mid-season figures being an upper bound on season-end values.
A unified and practical taxonomy for false discovery rate control in omics research
In a Nature Biotechnology Comment published on 13 November 2026, Thomas Burger, Xinzhou Ge and Jingyi Jessica Li propose a 2x2 matrix that provides a unified taxonomy of false discovery rate (FDR) control procedures in omics research, helping sequencing-based and mass-spectrometry-based researchers select the appropriate procedure family, or shift to potentially more rigorous alternatives, according to data characteristics and study design. The motivation is documented failures on both sides: permutation analyses show some differential analysis methods have actual FDR exceeding 20%, and tandem mass spectrometry evaluation found no search tool consistently controls FDR in data-independent acquisition analysis. The framework's limitation is that it is a classification framework rather than a new control procedure, and whether it truly reduces false discovery proportions still requires testing on specific data.
Opinion and commentary
5 takeaways from STAT’s investigation of the sprawling ‘three-parent IVF’ industry
An eight-month STAT investigation found the international reproductive tourism industry marketing mitochondrial replacement techniques, or "three-parent IVF," to older women lacks peer-reviewed human evidence. No peer-reviewed study supports that MRT can address age-related infertility in women over 35. Unpublished data from Kyiv's Nadiya clinic showed 1 live birth among 19 patients aged 36 to 44 after pronuclear transfer, versus 9 live births among 10 patients under 35.
Cancer vaccines show promise for treatment and prevention
A phase 3 trial of a personalized melanoma vaccine showed the strategy can improve patient outcomes, and Johns Hopkins researchers wrote in a companion NEJM editorial that this marks a turning point for therapeutic cancer vaccines. The article traces the route from GVAX and PD-1 checkpoint inhibitors to neoantigen selection based on tumor mutations, and notes that in 2024 a personalized vaccine combined with pembrolizumab showed activity in hepatocellular carcinoma.
This week in charts: Brain drugs are back on venture capitalists’ minds
Five neuroscience startups have together raised about $450 million in recent weeks, signaling renewed venture capital interest in brain drugs. Oyster Therapeutics completed a $60 million Series A led by 4BIO Capital with Eli Lilly participating. PepGen's mid-stage study in myotonic dystrophy type 1 showed its drug repaired an average of 46.5% of splicing errors, sending its shares up more than 90%, while cell therapy data presented after the American College of Rheumatology conference met a cool investor response, with Nkarta, Allogene and Fate shares falling more than 20%.
In brief
- First complete genomes for neglected malaria parasites revealedmedicalxpress.com
- Small RNA from surrounding cells promotes triple-negative breast cancer growthmedicalxpress.com
- Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial.BMJ
- An oxidative mutational signature in normal tissues of a monoallelic MUTYH carrierbiorxiv.org
